engagers
AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development
AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, T-cell engagers, tumor-activated immunotherapies, oncology, collaboration, biobucks deal
Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases
Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners
IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data
IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry
Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations
T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies
Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross